Heron Therapeutics Inc (NASDAQ:HRTX) – Investment analysts at Jefferies Group cut their Q2 2017 EPS estimates for shares of Heron Therapeutics in a report issued on Wednesday. Jefferies Group analyst B. Amin now anticipates that the biotechnology company will post earnings of ($0.99) per share for the quarter, down from their previous estimate of ($0.90). Jefferies Group has a “Buy” rating and a $29.00 price target on the stock. Jefferies Group also issued estimates for Heron Therapeutics’ Q3 2017 earnings at ($0.99) EPS, Q4 2017 earnings at ($0.99) EPS, FY2017 earnings at ($3.89) EPS, FY2018 earnings at ($2.30) EPS, FY2019 earnings at ($0.95) EPS, FY2020 earnings at $0.71 EPS and FY2021 earnings at $2.04 EPS.

A number of other equities analysts have also issued reports on the company. Noble Financial reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Friday. Cantor Fitzgerald reaffirmed a “buy” rating and set a $31.00 price target (up from $30.00) on shares of Heron Therapeutics in a research note on Thursday. Zacks Investment Research lowered Heron Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, May 9th. Aegis reaffirmed a “buy” rating on shares of Heron Therapeutics in a research note on Tuesday, March 21st. Finally, Needham & Company LLC assumed coverage on Heron Therapeutics in a research note on Monday, February 27th. They set a “buy” rating and a $28.00 price target for the company. One research analyst has rated the stock with a sell rating and ten have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $34.50.

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

WARNING: “Research Analysts Offer Predictions for Heron Therapeutics Inc’s Q2 2017 Earnings (HRTX)” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/05/15/research-analysts-offer-predictions-for-heron-therapeutics-incs-q2-2017-earnings-hrtx.html.

Shares of Heron Therapeutics (NASDAQ:HRTX) opened at 14.60 on Monday. The firm has a 50-day moving average price of $14.88 and a 200 day moving average price of $14.62. Heron Therapeutics has a one year low of $12.21 and a one year high of $24.00.

Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.94) by $0.06. The business had revenue of $3.63 million during the quarter, compared to the consensus estimate of $1.96 million.

Several large investors have recently made changes to their positions in HRTX. Legal & General Group Plc increased its stake in shares of Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the period. Venturi Wealth Management LLC bought a new stake in shares of Heron Therapeutics during the first quarter worth approximately $161,000. Wells Fargo & Company MN increased its stake in shares of Heron Therapeutics by 20.0% in the third quarter. Wells Fargo & Company MN now owns 11,167 shares of the biotechnology company’s stock worth $192,000 after buying an additional 1,858 shares during the period. Pacad Investment Ltd. bought a new stake in shares of Heron Therapeutics during the fourth quarter worth approximately $155,000. Finally, Old West Investment Management LLC bought a new stake in shares of Heron Therapeutics during the first quarter worth approximately $206,000.

In other news, VP Kimberly Manhard sold 21,542 shares of the stock in a transaction on Monday, April 24th. The stock was sold at an average price of $15.33, for a total transaction of $330,238.86. Following the completion of the sale, the vice president now owns 5,250 shares in the company, valued at approximately $80,482.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 20.31% of the stock is currently owned by corporate insiders.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

5 Day Chart for NASDAQ:HRTX

Receive News & Ratings for Heron Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.